Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced Solid Tumors, Showing Clinical Responses with Favorable Tolerability in PD-(L)1 Refractory Disease ...
In November 2022, Rubius Therapeutics Inc (NASDAQ: RUBY) initiated a process to explore a range of strategic alternatives and planned to engage an investment bank to act as a strategic advisor. But ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Rubius Therapeutics is in the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Cambridge red blood cell ...
Most cell therapies in development use a T cell or some other type of immune cell that’s engineered to perform a particular therapeutic task. Rubius Therapeutics makes its cell therapies from red ...
New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model Initial Clinical Results Expected in 2H’22 from Phase 1 Arm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results